Literature DB >> 34752310

Utility of Fine Needle Aspiration Cytology (FNAC) in the diagnosis of tuberculous lymphadenitis compared to GeneXpert in a tertiary health care center in Northern Odisha, India.

Kalyani Gouda1, Upasana Das1, Gunanidhi Dhangadamajhi2.   

Abstract

BACKGROUND: Diagnosis of extrapulmonary tuberculosis including tuberculous lymphadenitis (TBLN) is challenging because of its atypical clinical presentation, paucibacillary nature of mycobacteria at the infected sites, variation in sensitivity of a test to specimens collected by different methods and from different infected tissues.
METHODS: In the present study, suspected individuals for lymph node tuberculosis irrespective of age were enrolled prospectively and specimens were collected aseptically by fine needle aspiration (FNA). After the implementation of exclusion criteria, FNA specimens from a total of 278 cases of suspected TBLN were evaluated for cytomorphology (FNAC), presence of acid-fast bacillus (AFB) in smear microscopy and specific detection of mycobacterial DNA in cartridge-based nucleic acid amplification test (CBNAAT).
RESULTS: The results showed high prevalence of Type II (59.71%), followed by Type I (34.53%) and Type III (5.75%) pattern in FNAC. Non-type II patterns were significantly high in regions outside of the head and neck region (P = 0.031; OR = 2.125) and had an increasing trend of their occurrences with progression of age. The most affected age group was between 16 and 30 years with female preponderance documented in individuals below 45 years, whereas male preponderance was observed in higher age group patients, majority of whom had infected lymph nodes outside of HAN region (P = 0.063, OR = 1.998). The results also showed high sensitivity of CBNAAT (83.04%) method followed by FNAC (72.17%) with AFB smear exhibiting the disappointing results (sensitivity of 10.86%) compared to the CRS. High percentage of positivity was observed in Type III (AFB:25% vs CBNAAT: 100%) followed by Type II (AFB:10.2 vs CBNAAT: 76.5), while low detection was observed from samples with Type I (AFB:4.2 vs CBNAAT: 50). Interestingly, CBNAAT detection of TB was shown to be unaffected by gender, age and site of infection.
CONCLUSION: The study suggests a possible contributary role of age and gender for cytomorphological pattern distribution of TBLN at various body parts. Although FNAC detected TB in 77.1% of cases which were identified positive by CBNAAT and/or AFB, it is being solely based on cytomorphology cannot be used alone as a reliable diagnostic method for TBLN detection. Further, the negative results in CBNAAT for FNAC positive cases may not necessarily be non-TB cases and must be evaluated by other diagnostic modalities. We recommend for both cytomorphological investigation and CBNNAT for the fine needle aspirates from suspected TBLN and subsequent treatment to reduce the disease burden.
Copyright © 2021 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CBNAAT; Diagnosis; EPTB; FNAC; Tubercular lymphadenitis

Mesh:

Year:  2021        PMID: 34752310     DOI: 10.1016/j.ijtb.2021.01.005

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  3 in total

1.  Comparison of the Accuracy of Two Different Molecular Tests for the Diagnosis of Tuberculous Lymphadenitis Using Core Needle Biopsy Specimens: A Diagnostic Accuracy Study.

Authors:  Yanqin Shen; Weixian Jiang; Liwei Yao; Xudong Xu; Gang Chen
Journal:  Int J Gen Med       Date:  2022-05-27

2.  Integration of cytopathology with molecular tests to improve the lab diagnosis for TBLN suspected patients.

Authors:  Abay Atnafu; Kassu Desta; Selfu Girma; Dawit Hailu; Gebeyehu Assefa; Shambel Araya; Dinksira Bekele; Liya Wassie; Kidist Bobosha
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

Review 3.  Xpert MTB/RIF Assay for the Diagnosis of Lymph Node Tuberculosis in Children: A Systematic Review and Meta-Analysis.

Authors:  Hao-Kai Chen; Rui-Si Liu; Yi-Xuan Wang; En-Xiang Quan; Yuan-Hua Liu; Xu-Guang Guo
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.